About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Lonquek for Autologous Stem Cell Mobilization | Clinical Trials | Clareo Health

Back to clinical trial search

UNKNOWNPhase 1/2NCT02488382

Lonquek for Autologous Stem Cell Mobilization

The aim of this study is to evaluate the efficacy and tolerability of Lonquek which is a pegylated (long-acting) version of Filgrastim recombinant human G-CSF (G-CSF) in mobilizing sufficient number o...

Lead sponsor: Sheba Medical Center•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Arnon Nagler, MD

CONTACT

972 3 530 5830 a.nagler@sheba.health.gov.il

Avichai Shimoni, MD

CONTACT

9972 3 530 5830 ashimoni@sheba.health.gov.il

Sponsors

Lead Sponsor

Sheba Medical Center

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients with confirmed multiple myeloma or Hodgkins or non Hodgkin lymphoma at need of autologous stem cell transplantation.
•Disease must be chemosensitive or stable status to prior therapy before transplant.
•Age between 18 and 65 years inclusive.
•ECOG performance status 0, 1 or 2.
•Written informed consent.
•Adequate birth control in fertile patients.
•Patients with factors predicting poor mobilization including \>3 lines of previous chemotherapy, extensive irradiation, patients that received stem cell toxicity drugs like Melphalan, Fludarabine, \>2 courses of Revlimid, age \>65 years, platelets counts \<100x109/L, WBC\<2.5x109/L or WBC \> 35x109/L.
•Previous autologous stem cell transplantation.
•Inability to tolerate peripheral blood stem cell harvest.
•Peripheral venous access not possible.

Related studies

RECRUITINGPhase 1/2

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

NCT06953960 · Multiple Myeloma

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

NCT02682667 · Multiple Myeloma, Lymphoma, Non-Hodgkin, and more

RECRUITINGPhase 3

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

NCT06549595 · Untreated Follicular Lymphoma

Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma?

NCT06352242 · Diffuse Large B Cell Lymphoma

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

NCT05237986 · Lymphoma, Leukemia

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 17, 2017Terms

Trial snapshot

StatusUNKNOWN

PhasePHASE1/PHASE2

Enrollment24

Start dateJul 2017

Last updatedOct 17, 2017

Condition

Lymphoma Multiple Myeloma

Locations shown

Chaim Sheba Medical Center

Tel Litwinsky

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 17, 2017Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions